Piper Jaffray Reiterates Overweight Rating on DexCom
According to Piper Jaffray, DexCom (NASDAQ: DXCM) Overweight rating is reiterated.
Piper Jaffray said that DexCom released preliminary 4Q product revenue of $20.8M yesterday, in-line with PJC product revenue of $21.1M. “We rate DXCM shares at Overweight with a $14 PT based on a 6x multiple applied to our 2013 revenue estimate of $158.3M, discounted back a quarter at 20%. We are assuming trough net cash of ~$76M and 71M shares.”
DexCom closed yesterday at $8.86.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.